Glenmark Pharmaceuticals has received the final ANDA approval from the United States Food and Drug Administration (USFDA) to market Acyclovir ointment USP (5%), the genric version of Zovirax ointment of Valeant International Bermuda which is used in treatment of herpes viruses.
The Zovirax ointment (5%) achieved annual sales of approximately $110.3 million, as per IMS Health sales data for the year ending June 2017.
Glenmark, which targets 30 per cent of its revenue from innovative products by 2025, is authorised to distribute 121 products in the US market. The pharma major has 64 Abbreviated New Drug Applications (ANDAs) pending approval with the US food and drug regulator.
At a time when generic drug manufacturers are witnessing price erosion in the US market, Glenmark’s existing pipeline consists of at least four drugs.